Browsing Tag
PVP-I nasal spray
1 post
Firebrick Pharma (ASX:FRE) surges as Nasodine Phase 3 trial confirms 40% cold relief
Firebrick Pharma’s Phase 3 Nasodine trial confirms 40% symptom relief in cold patients. Discover how this could accelerate global sales and investor interest.